Neonatal indirect hyperbilirubinemia. Neonatal jaundice from other and unspecified causes
Conditions
Interventions
Intervention 1: Intervention group:The intervention group will receive oral drug of Ursodeoxycholic acid (UDCA) 10 mg/kg (1/6cc/kg) daily divided into 2 doses every 12 hours. UDCA 300 mg capsule(provi
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
2 Days to 15 Days
Inclusion criteria
Inclusion criteria: Exclusive breastfeeding, Age above 1 day Neonate born with gestational age 35 weeks or more Total bilirubin between 3 mg / dL less than the level required for intensive phototherapy treatment in the hospital and the level required for hospitalization Direct bilirubin levels below 2 mg / dL. Parent consent Infants whose parents agree not to use herbal or traditional medicines during the study period.
Exclusion criteria
Exclusion criteria: Rh incompatibility Uunderlying disease such as heart and liver disease Infection and septicemia Neonate of diabetic mother
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hospitalization rate. Timepoint: Weekly, from week 1 to 4 after the start of the intervention. Method of measurement: Asking the parents about admission in hospital for phototherapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Total bilirubin. Timepoint: Every 24 hours until the bilirubin reaches 3 mg / dl below the level required for intensive phototherapy. Method of measurement: Capillary method and diazo laboratory method.;Adverse effect of drug. Timepoint: Till 4 weeks after the start of the drug. Method of measurement: Asking the parents about adverse effect. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHourvash Akbari Haghighinejad
Shiraz University of Medical Sciences
Outcome results
None listed